These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26475335)

  • 21. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
    Jung J; Lee JS; Dickson MA; Schwartz GK; Le Cesne A; Varga A; Bahleda R; Wagner AJ; Choy E; de Jonge MJ; Light M; Rowley S; Macé S; Watters J
    Nat Commun; 2016 Aug; 7():12609. PubMed ID: 27576846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
    Shangary S; Qin D; McEachern D; Liu M; Miller RS; Qiu S; Nikolovska-Coleska Z; Ding K; Wang G; Chen J; Bernard D; Zhang J; Lu Y; Gu Q; Shah RB; Pienta KJ; Ling X; Kang S; Guo M; Sun Y; Yang D; Wang S
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3933-8. PubMed ID: 18316739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.
    Mahfoudhi E; Lordier L; Marty C; Pan J; Roy A; Roy L; Rameau P; Abbes S; Debili N; Raslova H; Chang Y; Debussche L; Vainchenker W; Plo I
    Oncotarget; 2016 May; 7(22):31980-92. PubMed ID: 26959882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
    Ray-Coquard I; Blay JY; Italiano A; Le Cesne A; Penel N; Zhi J; Heil F; Rueger R; Graves B; Ding M; Geho D; Middleton SA; Vassilev LT; Nichols GL; Bui BN
    Lancet Oncol; 2012 Nov; 13(11):1133-40. PubMed ID: 23084521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
    Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
    Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
    de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
    Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
    Wang B; Fang L; Zhao H; Xiang T; Wang D
    Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
    Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
    Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.